ALA-3000 vs AV-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ALA-3000
Developed by Alar Pharmaceuticals
NCT06965569 · Phase 1 · completed
This randomized, double-blind, placebo-controlled multiple-dose study gave subcutaneous ALA-3000 or placebo, with a standard oral antidepressant, to patients with treatment-resistant depression. All of its primary measures were safety and tolerability measures, which have no formal efficacy test, so there is no met or missed result. The company reports that side effects were mild to moderate and that no dissociation, sedation or psychosis-like symptoms were seen. Effects on depression scores were exploratory. The figures come from the company's press release.
Reported efficacy
Incidence of treatment-related adverse events (AEs) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal orthostatic blood pressure (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal heart rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal blood oxygen saturation (pulse oximetry) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal respiratory rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal body temperature (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal 12-lead electrocardiogram (ECG) parameters (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal hematologic findings (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal serum chemistry test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine cytologic findings (Baseline (prior to dosing) and the End of Study (Day 36) visit); Incidence and severity of dissociative symptoms assessed by Clinician Administered Dissociative States Scale (CADSS) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of treatment-emergent sedation assessed by Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of potential withdrawal symptoms assessed by Physician Withdrawal Checklist; 20-item (PWC-20) (Two weeks after last investigational product administration and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of suicide ideation assessed by Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination); Injection site tolerability based on injection site grading scale (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site pain visual analog scale (VAS) (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site evaluation for potential reactions and evidence of removal (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit): Primary, safety and tolerability (no formal efficacy test): treatment-related adverse events were mild to moderate in severity, and no dissociation, sedation or psychosis-like symptoms were observed. (not_applicable)
Result source: NCT06965569
AV-101
Developed by VistaGen Therapeutics
NCT02484456 · Phase 2 · completed
Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).
Reported efficacy
Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 1); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 2); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 3); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 7); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 13): Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) (missed)
Result source: NCT02484456
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALA-3000 | AV-101 |
|---|---|---|
| MADRS, change (acute) | —Not reported | 29.7 vs 27.1+2.6 vs placeboNCT024844565 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- ALA-3000
- —Not reported
- AV-101
- 29.7 vs 27.1+2.6 vs placeboNCT02484456
5 other results
- 30.4 vs 28.6 NCT02484456
- 29.9 vs 30.8 NCT02484456
- 29.5 vs 29.8 NCT02484456
- 28.8 vs 28.8 NCT02484456
- 29.3 vs 29.5 NCT02484456
CGI-S, change (acute)
- ALA-3000
- —Not reported
- AV-101
- —Not reported
MADRS response
- ALA-3000
- —Not reported
- AV-101
- —Not reported
MADRS remission
- ALA-3000
- —Not reported
- AV-101
- —Not reported
Relapse (% of patients)
- ALA-3000
- —Not reported
- AV-101
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALA-3000: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALA-3000: 0 of 4 rows · AV-101: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | AV-101 |
|---|---|
| Dropout rate | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | —1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result—1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
| Serious AEs | 5.3%1,080 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result5.3%1,440 mg for 1 Week NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | 1,080 mg for 1 Week headache 26.3% (placebo 15.8%) insomnia 15.8% (placebo 10.5%) musculoskeletal pain 15.8% (placebo 15.8%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 show 1 more result1,440 mg for 1 Week abdominal discomfort 5.3% (placebo 10.5%) asthenia 5.3% (placebo 0%) cold sweat 5.3% (placebo 0%) NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
AV-101
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALA-3000's landscape · AV-101's landscape